This listing has debuted. The live 5-factor QL signal switches on as soon as the engine has enough trading history.
We are a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Pain represents one of the largest and most pervasive therapeutic markets in the United States, driving an estimated 250 million prescriptions annually across acute and chronic settings; however, a continued reliance on opioids has contributed to a persistent public health crisis with significant societal and economic costs.
From Latigo Biotherapeutics Inc.'s Form 424B4 filed with the SEC on 2026-08-07. The issuer's own words — QuantLogix does not paraphrase it.
The audited financial statements for this issuer are in its Form 424B4 filed 2026-08-07. QuantLogix only publishes figures it can read directly from the filing.
From Latigo Biotherapeutics Inc.'s Form 424B4 filed with the SEC on 2026-08-07. Extraction is deterministic — the same filing always produces the same score; 742k characters of the document were scanned. Technology signals are lexical indicators, not a technical audit. Not investment advice; the debut itself will be this score's first grade.
Deal terms come from the public IPO calendar and change up to pricing — an expected date reads “to be announced” until the underwriters set it, and a range is not a final price. Implied market cap and float are arithmetic on those disclosed terms. Nothing on this page is a forecast or a recommendation.